Figure 3 | Hypertension Research

Figure 3

From: Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study

Figure 3

A representative fluorescence-activated cell sorting analysis of CD62-positive platelets before and after losartan administration. The B2 region indicates CD62-positive platelets. The percent positive platelet results were calculated using B2/(B1+B2) × 100%, which yielded 7.35%, 2.36% and 0.96% before and at 8 and 12 weeks (W) after initiating losartan use, respectively. The left upper panel shows the pre-treatment (0 W) results, the right upper panel shows the results 8 W after initiating losartan therapy at 50 mg and the left lower panel shows the results 12 W after initiating losartan therapy and increasing the dose to 100 mg after W 8. Blue dots represent CD42b-positive/CD62P-positive particles, indicating active platelets; green dots represent CD42b-positive/CD62P-negative particles, indicating inactive platelets; and red dots represent CD42b-negative/CD62P-negative particles, indicating particles other than platelets. FITC, fluorescein isothiocyanate; PE, phycoerythrin. A full color version of this figure is available at the Hypertension Research journal online.

Back to article page